leadf
logo-loader
viewEmyria Ltd

Emerald Clinics raises $2.2 million to continue expansion of clinical services

The company achieved a record month in July and closed a major data deal in the UK.

Emerald Clinics Ltd - Emerald Clinics raises $2.2 million as it pursues near-term commercial opportunities
Emerald is planning to change its name to Emyria

Emerald Clinics Ltd (ASX:EMD) has raised $2.2 million via the placement of shares at 8 cents each to fund the expansion of its clinical services, research and development and business development opportunities.

The company’s share placement received strong demand from a combination of new and existing institutional and sophisticated investors in Australia and international markets.

Emerald is focussed on generating real-world evidence using its network of specialist medical clinics and purpose-built, remote patient monitoring software and technology.

The company believes the infusion of new capital will add momentum to its business, buoyed by record monthly sales in July and signing of a major data deal in the UK.

“New capital will add to our momentum”

Emerald CEO Michael Winlo said: “We’re appreciative of the strong response to this capital raising as investors see the recent progress the business has made and its potential.

“Coming off a record month in July and a major data deal in the UK, the injection of new capital will add to our momentum as we pursue various near-term commercial opportunities.”

Name change

Emerald has announced its intention to change its name to Emyria Limited, pending shareholder approval at a general meeting to be held on September 18, 2020.

Quick facts: Emyria Ltd

Price: 0.08 AUD

ASX:EMD
Market: ASX
Market Cap: $16.91 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Emyria Ltd named herein, including the promotion by the Company of Emyria Ltd in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Zelira Therapeutics and Emyria team up for 'disruptive' autism spectrum...

Zelira Therapeutics Ltd's (ASX:ZLD) (OTCQB:ZLDAF) (FRA:G1G) Richard Hopkins and Emyria Ltd's (ASX:EMD) Michael Winlo speak to Proactive's Andrew Scott after announcing they've entered into an agreement to conduct an observational trial for patients diagnosed with autism spectrum disorder (ASD)...

3 weeks ago

2 min read